Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”

Detalles Bibliográficos
Autores principales: Krebs-Brown, Axel, Munafo, Alain, Gaikwad, Sumedh, Urgatz, Bogumila, Castello-Bridoux, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007443/
https://www.ncbi.nlm.nih.gov/pubmed/31802400
http://dx.doi.org/10.1007/s40262-019-00847-0
_version_ 1783495320057937920
author Krebs-Brown, Axel
Munafo, Alain
Gaikwad, Sumedh
Urgatz, Bogumila
Castello-Bridoux, Claire
author_facet Krebs-Brown, Axel
Munafo, Alain
Gaikwad, Sumedh
Urgatz, Bogumila
Castello-Bridoux, Claire
author_sort Krebs-Brown, Axel
collection PubMed
description
format Online
Article
Text
id pubmed-7007443
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-70074432020-02-24 Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?” Krebs-Brown, Axel Munafo, Alain Gaikwad, Sumedh Urgatz, Bogumila Castello-Bridoux, Claire Clin Pharmacokinet Letter to the Editor Springer International Publishing 2019-12-05 2020 /pmc/articles/PMC7007443/ /pubmed/31802400 http://dx.doi.org/10.1007/s40262-019-00847-0 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Krebs-Brown, Axel
Munafo, Alain
Gaikwad, Sumedh
Urgatz, Bogumila
Castello-Bridoux, Claire
Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_full Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_fullStr Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_full_unstemmed Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_short Comment on: “Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?”
title_sort comment on: “why were more than 200 subjects required to demonstrate the bioequivalence of a new formulation of levothyroxine with an old one?”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007443/
https://www.ncbi.nlm.nih.gov/pubmed/31802400
http://dx.doi.org/10.1007/s40262-019-00847-0
work_keys_str_mv AT krebsbrownaxel commentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT munafoalain commentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT gaikwadsumedh commentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT urgatzbogumila commentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone
AT castellobridouxclaire commentonwhyweremorethan200subjectsrequiredtodemonstratethebioequivalenceofanewformulationoflevothyroxinewithanoldone

Ejemplares similares